The Korea Advanced Institute of Science and Technology (KAIST) has recently acquired South Korea’s first STYX high-throughput screening system, developed by Atrandi Biosciences. This cutting-edge addition to KAIST’s research infrastructure is set to enhance the institute’s capabilities in single-cell analysis and ultra high-throughput screening. By leveraging the full potential of the STYX system, researchers anticipate groundbreaking discoveries that will solidify KAIST’s role as a leader in life sciences research.

Professor Sungmin Son from KAIST’s Bio and Brain Engineering department is heading the first Korean team to utilize the advanced features of the STYX platform. The team aims to develop high-throughput technologies to analyze molecular and cellular properties at the individual level. “STYX provides a seamless, turn-key sorting solution while offering flexibility to develop and integrate new functionalities. Its versatility makes it an invaluable asset for protein engineering and the innovative single-cell screening projects planned for my lab,” said Professor Son.

Founded in 2016, Atrandi Biosciences has emerged as an innovator in microfluidics technology. The company’s portfolio includes microfluidic platforms for ultra-high-throughput screening and semi-permeable capsule technology for single-cell whole genome sequencing. With over 100 hardware systems installed globally, primarily in Europe and North America, the installation at KAIST marks a strategic expansion into the APAC region.

“South Korea is quickly establishing itself as a global leader in the life sciences industry, distinguished by exceptional growth and innovation. Its highly skilled talent pool, combined with a robust network of research institutes, universities, and private companies, makes it one of the most dynamic markets in biotechnology. We are thrilled to support top-notch science in the region,” said Juozas Nainys, PhD, CEO of Atrandi Biosciences.

This development not only highlights the synergy between cutting-edge technology and scientific research but also reflects strengthening ties between Lithuania and South Korea, which is further exemplified by the forthcoming establishment of the South Korean embassy in Lithuania. 

This development underscores the synergy between cutting-edge technology and scientific research while also reflecting the strengthening relationship between Lithuania and South Korea. This partnership is further highlighted by the upcoming establishment of the South Korean embassy in Lithuania.

Ricardas Slepavicius, the Ambassador of Lithuania to South Korea, remarked, “This is one of the examples of our strong commitment to working together in the biotech field, using our shared knowledge and skills to solve global problems and make new advancements in healthcare. I believe it will be a great example for future projects between Lithuania and South Korea, leading to even more successful collaborations.”